Search

everythinglearnresearchcommunity

for

Search:↓

Squaric acid dibutylester helps hair growth by increasing certain immune cells in the skin.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

Diphencyprone (DCP) is an effective treatment for severe alopecia areata and resistant warts, with some risks.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

CENPV, a new partner of CYLD, helps regulate ciliary acetylated tubulin and is overexpressed in certain skin tumors.

Targeting ornithine decarboxylase can help prevent skin cancer.

Transcutaneous vaccination using nanoparticles can enhance immune responses and reduce basal cell carcinomas.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Compounds from Etlingera alba may help treat Triple Negative Breast Cancer.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

A blood pressure drug, diltiazem, may also help treat influenza.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

TLR7-based compounds may help manage chemotherapy-induced hair loss.

A new compound from Royoporus badius activates immune cells and induces inflammatory responses.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

A specific genetic trait in tumor cells is linked to longer survival without disease in certain lymphoma patients.

The new antibody, TYHF-1, specifically targets certain hair-related structures.

The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.

Cepharanthine shows promise as a COVID-19 treatment.

ZSYY001 is safe, well-tolerated, and shows promise for treating advanced solid tumors.

Pyrene excimer nucleic acid probes are promising for detecting biomolecules accurately with potential for biological research and drug screening.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

Patients with alopecia areata on ritlecitinib responded well to tetanus and meningococcal vaccines.

SM04755 may be an effective topical treatment for psoriasis.